Clinical Study
Fibroblast Growth Factor and Mineral Metabolism Parameters among Prevalent Kidney Transplant Patients
Table 1
Clinical and laboratory characteristics of patient cohort. Both numbers and percentages reported.
| | Age (years) | 46.9 ± 11.2 | | Male | 66 (62%) | | Caucasian | 93 (88%) | | Diabetes (pre- or posttransplant) | 16 (15%) | | CKD | | | Stage 1T & 2T | 58 (55%) | | Stage 3T & 4T | 48 (45%) | | Cardiovascular disease | 18 (17%) | | Bone disease | | | Osteopenia/osteoporosis | 20 (19%) | | Avascular necrosis | 2 (2%) | | Multiple transplants | 14 (13%) | | Donor source | | | Living donor | 70 (66%) | | Deceased donor | 37 (34%) | | Preemptive transplantation | 33 (31%) | | Prevalence of delayed graft function | 16 (15%) | | Received induction therapy | 26 (29%) | | Acute rejection episodes | 15 (14%) | | Immunosuppression | | | Prednisone | 58 (55%) | | Tacrolimus | 94 (89%) | | Mycophenolate Mofetil | 86 (81%) | | Posttransplant duration (months)* | 12.8 (7.5–30.9) | | eGFR (mL/min/m2) | 62.9 ± 21.0 | | Serum calcium (mg/dL) | 9.6 ± 0.5 | | Serum phosphate | 3.1 ± 0.7 | | Serum PTH levels (pg/mL)* | 90 (58–172) | | Hemoglobin (g/dL) | 13.3 ± 1.8 | | Serum albumin (g/dL) | 4.0 ± 0.3 | | Plasma FGF-23 (pg/mL)* | 16 (12–22) |
|
|
*median, 25th and 75th percentile, CKD: chronic kidney disease, eGFR: estimated glomerular filtration rate, PTH: parathyroid hormone, FGF-23: fibroblast growth factor-23.
|
